KRAS and colorectal carcinoma: The prognostic value of clinicopathological factors [21,22] and investigative biomarkers [23] may well differ in men and women, but to our best knowledge, no previous studies have investigated sex-related differences in the prognostic impact of KRAS and BRAF mutation in CRC.